Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04262960
Other study ID # 07034918000005327
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2019
Est. completion date April 2021

Study information

Verified date February 2020
Source Hospital de Clinicas de Porto Alegre
Contact Ruy Silveira Morais Filho, PhD
Phone +55 5133598289
Email rfilho@hcpa.edu.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study the investigators will evaluate chronotype, food intake pattern, and cardiovascular risk markers of elder individuals with OSA, in use of CPAP, when submitted to two weeks of CPAP withdrawal.


Description:

Obstructive sleep apnea (OSA) is a growing public health problem affecting up to 95% of older populations. This sleep disorder influences glucose metabolism, leptin and grelin levels, promotes sympathetic overactivity, and is associated to increased cardiovascular events. All awake-sleep processes are determined by clock-genes and by external factors such as sunlight, physical activity, feeding, sleep, and chronotype. Chronotype is the propensity for the individual to wake and sleep at a particular time during a 24-hour period, and is categorized as morning, intermediate or evening chronotype. Individuals with morning chronotype are more alert in the morning and choose an earlier bedtime. Individuals with evening chronotype have more inclination for evening activities and choose a later bedtime. And those classified as intermediate chronotype show low or no preference for either morning or evening hours for activities. Individuals with evening chronotype tend to have higher nocturnal food intake, body mass index (BMI), levels of stress hormones, and more sleep apnea episodes. In humans, changes in sleep pattern for a few days are sufficient to affect food intake pattern. Two days of partial sleep deprivation increases hunger and appetite for calorie-dense foods with high carbohydrate content. Food composition, quantity, timing, and rhythmicity of meals impact on microbiota and metabolism, increasing basal level of inflammation and age related diseases. The aging process comes with an increase in the molecules involved in hypercoagulable states, such as plasminogen activator inhibitor 1 (PAI-1), a protein induced by inflammatory mediators, which creates a prothrombotic state, resulting in a pathological deposit of fibrin followed by tissue damage. The increase in PAI-1 expression is related to the development of tissue pathologies such as thrombosis, fibrosis and cardiovascular disease. Adults with moderate-to-severe OSA have higher levels of PAI-1, and respond to two weeks of Continuous Positive Airway Pressure (CPAP) with a 50% reduction in this antifibrinolytic enzyme. The impact of CPAP use on chronotype, food intake pattern, and cardiovascular risk markers have never been studied in elder individuals with OSA.


Recruitment information / eligibility

Status Recruiting
Enrollment 44
Est. completion date April 2021
Est. primary completion date April 2020
Accepts healthy volunteers No
Gender All
Age group 65 Years to 75 Years
Eligibility Inclusion Criteria:

- Age 65 to 75 years

- Previous diagnosis of OSA with AHI> 30 events / hour

- Body mass index below 34,9 kg/m2

- Use of CPAP for more than one year, with an average duration of at least 6 hours per night, confirmed by the device's memory

- Evidence in the device that you have stopped using it previously, for at least two weeks, with no relevant symptoms

- Use of automatic CPAP device with full memory for at least one year, preferably using device model with internet data access

- Subjects physically active and willing to provide informed consent

- Subjects willing to attend visits and blood collections in series

Exclusion Criteria:

- History of myocardial infarction, stroke or transient ischemic attack (TIA) or peripheral vascular disease.

- History of chronic diseases such as diabetes mellitus ( A fasting plasma glucose (FPG) level of 152 mg/dL or A1C > 7,5 % ), uncontrolled severe hypertension (SBP >180 DBP > 110), renal failure on dialysis, cancer, autoimmune or liver disease

- A significant history of medical or psychiatric disease that may decompensate with altered sleep patterns or impair participation in the trial

- Severe or unstable clinical conditions that may be exacerbated by discontinuation of CPAP (cardiac, pulmonary, renal or other organ disorders not yet treated or worsening of symptoms in the last two months, eg cardiac arrhythmias, congestive heart failure and oxygen-dependent lung disease)

- Another primary sleep disorder that requires intervention with medications.

- Patients with unusual sleep or wake habits, including shift work.

- Professional driver or who crosses paths of more than one hour driving, in which the s sleepiness can be risk of accident.

Study Design


Intervention

Device:
Device: active CPAP
auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
Device: sham-CPAP
The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.

Locations

Country Name City State
Brazil Hospital de Clinicas de Porto alegre Porto Alegre Rio Grande Do Sul

Sponsors (1)

Lead Sponsor Collaborator
Hospital de Clinicas de Porto Alegre

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary The association between withdrawal CPAP with chronotype, food intake pattern and cardiovascular risk markers. Chronotype as defined by the MEQ chronotype categories; food intake pattern dietary assessed by a 3 day food intake diary, and Plasminogen activator inhibitor type 1 (pg/mL) and plasminogen (ng/mL) measured from blood samples by ELISA. 4 weeks
Secondary Plasminogen activator inhibitor type 1 Plasminogen activator inhibitor type 1 (pg/mL) measured from a blood sample by ELISA. 1 week before and two weeks after randomization
Secondary Plasminogen Plasminogen (ng/mL) measured from a blood sample by ELISA. 1 week before and two weeks after randomization
Secondary Blood pressure We will be measuring Systolic and Diastolic Blood Pressure by Ambulatory 24-hour blood pressure monitoring. 1 week before and two weeks after randomization
Secondary Chronotype Morningness Eveningness Questionaire (MEQ) inquires about daily performance and preferred sleep schedule (score range 16 to 86) and presents 19 questions. Based on their scores, individuals will be classified as morning (score: 50-86) or evening type (score: 16-49). 1 week before and 1 week after randomization - MEQ 1 week before and 2 weeks after randomization
Secondary Sleep habits Sleeping and awake periods will be assessed by a wrist actigraphy monitor (ActTrust, Condor Instruments, São Paulo - Brazil) according to the Cole-Kripke algorithm, and the duration expressed in minutes. 1 week before and 1 week after randomization - MEQ 1 week before and 2 weeks after randomization
Secondary Dietary intake Participants will record food intake for three consecutive days, including two days of the week and one day of the weekend. During the visit, they will receive verbal instructions on how to register, as well as written instructions consisting of printed material showing the portion sizes of the food and how to fill the journal. Information about mealtimes will also be obtained. Data will be analyzed using a Brazilian Nutrition Software (Dietbox) and expressed in calories an in percentage of total caloric intake. A meal will be considered as an occasion to eat when consumption exceeds 20 kcal. Higher caloric intake in the evening will be associated to evening chronotype. For three days before and after randomization
Secondary Autonomic modulation Autonomic modulation will be evaluated by low frequency (LF) and high frequency (HF) components of heart rate spectral analysis, at rest and during sympathetic stimulation with the Stroop Color Word Test, expressed in ms2/Hz and in normalized units. The amount of increase in LF/HF ratio during sympathetic stimulation will reflect the autonomic modulation integrity. 1 week before and two weeks after randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05489562 - Use of Intraoral Suction and Its Effects on Obstructive Sleep Apnea N/A
Recruiting NCT05717959 - Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device N/A
Recruiting NCT06008626 - Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea N/A
Completed NCT03122639 - Endothelial Function in Obstructive Sleep Apnea Early Phase 1
Completed NCT03940781 - Effects of Rehabilitation for Patients With Obstructive Sleep Apnea N/A
Recruiting NCT05289063 - Vascular Endothelial Dysfunction in Sleep Apnea Phase 1
Not yet recruiting NCT05268471 - Cost-effectiveness Analysis and Conditional Response to the Effect of Positional Devices in Obstructive Sleep Apnea N/A
Active, not recruiting NCT04864652 - Safety and Dosing Study of the CHILLS Cryotherapy for the Treatment of OSA N/A
Enrolling by invitation NCT05433883 - The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness N/A
Recruiting NCT06103630 - Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device N/A
Recruiting NCT06283095 - Management of Obstructive Sleep Apnea Syndrome by Expansion Palatoplasty N/A
Completed NCT03156283 - SleepWell24: An Innovative Smartphone Application to Improve PAP Adherence N/A
Completed NCT03362385 - OSA-ACS Project: Association of OSA and CPAP Therapy With Outcomes in ACS Patients
Recruiting NCT06447818 - Changes in Difficult Airway Markers After Surgery for Obstructive Sleep Apnoea Syndrome
Completed NCT04643782 - Comparative Study of the ANNE™ One System to Diagnose Obstructive Sleep Apnea N/A
Recruiting NCT03463785 - Does Race Make a Difference in Obstructive Sleep Apnea?
Recruiting NCT03618719 - Impact of Intermittent Hypoxia on the Function of the Phagocytes
Completed NCT03048604 - BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA) N/A
Recruiting NCT05290350 - Long COVID-19 Fatigue and Obstructive Sleep Apnea
Recruiting NCT05739617 - Comprehensive Respiratory Training Exercise Program in Obstructive Sleep Apnea N/A